Dare Bioscience, Inc. annual report, FY2021

Dare Bioscience, Inc. — FY2021 Form 10-K

Reporting period: Fiscal year ended December 31, 2021. This is an annual filing, not a standalone fourth-quarter report. Financial comparisons below are FY2021 versus FY2020. The filing was signed March 31, 2022.

Business context

Dare is a clinical-stage biopharmaceutical company focused on women’s health, including contraception, fertility, and vaginal and sexual health. Its first FDA-approved product, XACIATO, was approved in December 2021 for bacterial vaginosis in females 12 and older; it had not yet launched and the company had not generated revenue through year-end. In March 2022, after the reporting period, Dare signed an exclusive global commercialization license for XACIATO with Organon. U.S. launch was expected in Q4 2022.

Key programs include Ovaprene, a hormone-free monthly contraceptive; Sildenafil Cream 3.6% for female sexual arousal disorder; DARE-HRT1 for menopausal symptoms; DARE-VVA1 for vulvar and vaginal atrophy; and earlier-stage fertility and contraception programs.

Financial performance and liquidity

MetricFY2021 / Dec. 31, 2021FY2020 / Dec. 31, 2020
Revenue$0$0
General and administrative expense$8.35 million$6.55 million
Research and development expense$30.62 million$20.77 million
Total operating expenses / operating loss$39.07 million / $(39.07) million$27.40 million / $(27.40) million
Net loss$(38.70) million$(27.40) million
Basic and diluted loss per share$(0.63)$(0.91)
Cash used in operating activities$(28.76) million$(25.23) million
Cash and cash equivalents$51.67 million$4.67 million
Working capital$39.24 million$(0.68) million
Total assets / total liabilities$55.81 million / $17.05 million$7.55 million / $8.70 million

Margins are not meaningful because the company reported no revenue. The net loss included a $369,887 gain from forgiveness of the company’s Paycheck Protection Program loan. No note payable remained at December 31, 2021. Lease liabilities were $270,546, all current.

Financing provided $75.85 million in cash in FY2021, primarily from equity issuance; investing used $14,524. Cash increased by $47.00 million for the year. The company issued approximately 41.1 million shares through equity offerings and its equity line, generating $75.31 million net proceeds, and also issued shares for an acquisition milestone. Common shares outstanding rose from 41.60 million at year-end 2020 to 83.94 million at year-end 2021.

The independent auditor issued an unqualified opinion on the financial statements but highlighted substantial doubt about Dare’s ability to continue as a going concern. Management stated that, based on its operating plan, available cash was insufficient to meet working-capital and other liquidity needs for the 12 months following issuance of the financial statements, making additional capital or significant operating cuts necessary.

Material changes versus FY2020

  • Net loss widened by $11.30 million, or 41%; operating expenses rose by 43%.
  • R&D expense increased by $9.85 million, or 47%, driven principally by about $7.7 million of additional Sildenafil Cream Phase 2b costs and higher Ovaprene, manufacturing, regulatory, and earlier-stage program costs. Completion of XACIATO’s Phase 3 trial partly offset the increase.
  • G&A expense increased by $1.80 million, or 28%, including higher personnel, commercial-readiness, and stock-based compensation costs.
  • Cash rose substantially following $75.85 million of financing proceeds, while operating cash use also increased.
  • Accumulated deficit reached $110.13 million. Stockholders’ equity improved to $38.75 million from a $1.15 million deficit, largely reflecting equity issuance.

Outlook, commentary, and key risks

  • Spending: Management expected 2022 R&D expense could exceed twice FY2021 levels if programs advanced as planned, including up to $4.0 million in development milestone payments. G&A expense was expected to rise 15%–20%, reflecting personnel and overhead as well as XACIATO readiness and supply activities.
  • XACIATO / Organon: The post-year-end agreement provides for a $10 million non-refundable payment after the agreement becomes effective, a $2.5 million U.S. first-sale milestone, tiered double-digit royalties, and up to $180 million in additional regulatory and commercial milestones. Effectiveness was subject to closing conditions, including antitrust clearance; payments and sales are not assured. Organon may terminate after the first anniversary on 120 days’ notice.
  • Ovaprene: FDA discussion of the planned pivotal Phase 3 study was ongoing through an IDE pre-submission process; the company targeted study commencement in 2022. Dare committed $5.5 million to NICHD for the study. Bayer’s U.S. license would become effective only if Bayer elected to pay a further $20 million; Bayer could terminate on 90 days’ notice.
  • Other development: Sildenafil Cream Phase 2b enrollment was slower than expected; an interim analysis was anticipated in 2022. DARE-HRT1 had positive Phase 1 pharmacokinetic and tolerability results, with a Phase 1/2 study planned in Australia for Q2 2022. Topline DARE-VVA1 data were anticipated in the second half of 2022.
  • Grant support: Dare received $11.45 million in 2021 under a Gates Foundation award of up to $48.95 million for DARE-LARC1 preclinical development through 2026. Further payments depend on milestones and compliance; the award does not assure success or fund later clinical development.
  • Principal risks: Continued operating losses and financing dependence; potential dilution and limits on future capital raising; uncertain clinical and regulatory outcomes; slower enrollment; reliance on collaborators, CROs, and single-source manufacturers; supply-chain disruption; competitive and reimbursement pressure; and the possibility that licensees do not launch, commercialize, or continue their agreements. COVID-19 had contributed to slower Sildenafil Cream enrollment and delays in some earlier programs, though management said it had not materially harmed the business overall to date.
  • Other matters: No material pending legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the company was not required to obtain an auditor attestation of internal controls.

Important facts for investors to verify

  • Whether the Organon license became effective and whether the $10 million payment and first-sale milestone were received; confirm actual launch timing, sales, and royalty terms in subsequent filings.
  • Current cash, operating cash burn, financing raised after year-end, and whether liquidity has improved enough to address the disclosed going-concern uncertainty.
  • Ovaprene IDE status, Phase 3 start and enrollment, supply readiness, and Bayer’s decision regarding its $20 million license activation payment.
  • Sildenafil Cream enrollment and interim-analysis results, plus updated cost and timing estimates for its Phase 2b trial.
  • Whether contingent grant milestones for DARE-LARC1 were achieved and the extent of funding available for development beyond the preclinical stage.
  • Subsequent share issuance, outstanding warrants and options, and resulting dilution; year-end common shares were 83.94 million.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.